On January 6, 2026, shareholders at PRF Technologies Ltd. (formerly PainReform Ltd.) approved a corporate name change to better capture the company’s transition from a single-product pharmaceutical concern to a diversified innovation platform. The rebrand, effective immediately, preserves the Nasdaq ticker PRFX while reflecting a broadened focus across specialty pharmaceuticals, advanced drug-delivery technologies and AI-driven renewable-energy analytics. Chairman and Interim CEO Dr. Ehud Geller highlighted that the company’s revenue drivers now span multiple high-growth markets rather than relying solely on its PRF-110 non-opioid extended-release therapy, positioning PRFX for more stable, multi-stream cash flows and reduced program risk.

PRF’s majority ownership of LayerBio has opened a scalable ophthalmology platform anchored by OcuRing™-K, a patented, bioerodible, sustained-release ocular implant targeting post-cataract surgery pain and inflammation. With cataract procedures exceeding 20 million annually worldwide, the addressable market for dropless ocular therapies is estimated in the low single-digit billions of dollars. OcuRing™-K eliminates patient adherence challenges by delivering localized therapy from a single intraoperative application and is advancing into Phase II clinical development. LayerBio’s platform also supports future indications in glaucoma and diabetic retinopathy, offering PRFX a clear pathway to capture incremental value beyond its lead program.

Parallel to its pharmaceutical initiatives, PRFX has launched DeepSolar, an AI-powered solar analytics and digital asset-management business serving utility-scale solar operators. DeepSolar’s Smart TDD service provides next-generation technical due diligence for asset transactions, warranty reviews and underperformance diagnostics, while DeepSolar Predict—developed within NVIDIA’s Connect Program—aims to improve solar production forecasts by up to 15% versus legacy models. An automated AI reporting engine further accelerates insight generation across project development, operations and financing. Having progressed from internal R&D to early commercial pilots in the U.S. Southwest and Europe, DeepSolar is engaging customers on multi-year agreements as global solar capacity ages and transaction activity climbs.

PRFX’s management underscores a disciplined approach to capital allocation and platform scalability, aiming to balance R&D investment across PRF-110, OcuRing™-K and DeepSolar while maintaining a strong cash runway into late 2027. The company reports cash and investments of $18 million as of December 31, 2025, following a July equity raise that secured $10 million in gross proceeds. With three distinct growth engines—postoperative pain, ophthalmology and clean-energy analytics—PRFX targets total addressable markets exceeding $50 billion combined, and expects to reach breakeven on a consolidated basis by mid-2028.